Ezetimibe/simvastatin 10/20 mg versus simvastatin 40 mg in coronary heart disease patients

Averna, Maurizio; Zaninelli, Augusto; Grazie, C. Le; Gensini, Gian Franco

doi:10.1016/j.jacl.2010.05.002

Cited by 11 publications

(7 citation statements)

References 36 publications

(33 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A total of 568 studies was hit initially, and 49 articles were retrieved for evaluation at length; and finally, 20 RCT that satisfied the inclusion criteria were analysed. The characteristics of these 20 studies are listed in Table . The quality of the reporting is shown in Figure ; 13 trials had complete information for assessing randomisation, and five trials had adequate blinding.…”

Section: Resultsmentioning

confidence: 99%

Safety of coadministration of ezetimibe and statins in patients with hypercholesterolaemia: a meta‐analysis

Luo

Huang

Ren

et al. 2015

Internal Medicine Journal

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

Safety of coadministration of ezetimibe and statins in patients with hypercholesterolaemia: a meta‐analysis

Luo

Huang

Ren

et al. 2015

Internal Medicine Journal

View full text Add to dashboard Cite

show abstract

“…Finally, 11 studies (n = 1926 participants) were eligible for the meta-analysis ( Fig. 1) [13][14][15][16][17][18][19][20][21][22][23].…”

Section: Study Selectionmentioning

confidence: 99%

Efficacy of combination therapy with ezetimibe and statins versus a double dose of statin monotherapy in participants with hypercholesterolemia: a meta-analysis of literature

et al. 2020

View full text Add to dashboard Cite

Background: The aim of this study was to compare and summarize the lipid-altering effects of combination therapy with ezetimibe and statins (E/S) and a double dose of statin (D/S) monotherapy on patients with hypercholesterolemia. Methods: We conducted search on 2 medical databases, PubMed and EMBASE to identify all relevant studies. A meta-analysis was performed to clarify the efficacy in the two groups. Only double-blind Randomized controlled study (RCTs) of efficacy evaluation in the two groups with ezetimibe and statins and a double dose of statin in participants with hypercholesterolemia that examined low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC) and high-density lipoprotein (HDL) were included. Two reviewers extracted data from all primary studies independently. The primary data were the level of LDL-C, TC and HDL-C concentrations at the end point and are expressed as mean and standard deviation (SD). Results: A total of 11 double-blind, active or placebo-controlled studies with 1926 hypercholesterolemia adults randomized to ezetimibe 10 mg added to ongoing statins (N = 994) or statin titration (doubling) (N = 932) were pooled for the global meta-analysis. The effect size between treatment groups within individual studies was assessed by weighted mean difference (MD) using a random-or fixed-effect model. The result showed that the participants in E/S group get obvious lower LDL-C [MD =-13.14 mg/dL, 95%CI (−16.83,-9.44), p = 0.00001] and TC concentration [MD =-23.79 mg/dL, 95%CI (−38.65,-8.93), p = 0.002] from baseline to follow-up, comparing to the D/ S group. Besides, no significant between-group differences were observed for concentrations of HDL-C [MD = 0.46 mg/dL, 95%CI (− 1.14, 2.06), p = 0.57]. According to subgroup analysis, the combination of ezetimibe and atorvastatin (10 mg) [MD =-16.98 mg/dL, p < 0 .0001] or simvastatin (20 mg) [MD =-17.35 mg/dL, p < 0 .0001] showed stronger ability of reducing LDL-C than combination of ezetimibe and rosuvastatin (10 mg) [MD =-9.29 mg/dL, p = 0.05]. The efficacy of short-term (endpoint time between 6 to 16 week) and long-term (52 week) treatment in the LDL-C between two groups did not show significant differences. Besides, only participants from Asia treated with combination therapy were associated with a significant lower LDL-C concentration [MD =-14.7 mg/dL, p < 0 .0001].

show abstract

“…Statins combined with other lipid-lowering agents may be a choice for those patients. Several studies have investigated the effects of statin/eze as compared with high-intensity statin monotherapy ( 22 – 25 ). Although the dosages of agents used may differ between various studies, the present results were consistent or similar to those of previous studies.…”

Section: Discussionmentioning

confidence: 99%

Effectiveness and safety of combinational therapy compared with intensified statin monotherapy in patients with coronary heart disease

Liu

Xiao

2018

Exp Ther Med

View full text Add to dashboard Cite

Reducing the plasma levels of low-density lipoprotein-cholesterol (LDL-C) is critical for patients with coronary heart disease (CHD). Conventional treatment with statins alone may not achieve the goal of lowering LDL-C due to drug intolerance or resistance. The present study evaluated the effectiveness and safety of combining statin with another lipid-lowering agent in the management of dyslipidemia in CHD patients. A total of 180 patients with CHD were divided into three therapeutic groups (n=60 in each): Statin/colesevelam group (20 mg atorvastatin and 10 mg colesevelam daily), statin/ezetimibe group (20 mg atorvastatin and 10 mg ezetimibe daily) and high-intensity statin monotherapy group (30 mg atorvastatin daily). The baseline plasma lipid levels were measured. The duration of the treatment was eight weeks and the side effects were noted at one year's follow-up. After eight weeks' treatment, the mean plasma level of LDL-C was reduced by 45.2, 44.8 and 30.0% in the statin/colesevelam, statin/ezetimibe and statin monotherapy group, respectively. The reduction of LDL-C in the combinational therapy groups was greater than that in the statin monotherapy group (P<0.05). The proportion of patients achieving the goal of lowering LDL-C in the combinational therapy groups was higher than that in the statin monotherapy group. The effectiveness of reducing lipids was similar in the two combinational statin/colesevelam and statin/ezetimibe groups. Rates of adverse events were not significantly different among the three groups. In conclusion, statins combined with colesevelam or ezetimibe were more effective in reducing plasma LDL-C levels than high-intensity statin monotherapy. This combinational therapeutic strategy may be an alternative for patients that are resistant or intolerant to statins.

show abstract

Ezetimibe/simvastatin 10/20 mg versus simvastatin 40 mg in coronary heart disease patients

Cited by 11 publications

References 36 publications

Safety of coadministration of ezetimibe and statins in patients with hypercholesterolaemia: a meta‐analysis

Safety of coadministration of ezetimibe and statins in patients with hypercholesterolaemia: a meta‐analysis

Efficacy of combination therapy with ezetimibe and statins versus a double dose of statin monotherapy in participants with hypercholesterolemia: a meta-analysis of literature

Effectiveness and safety of combinational therapy compared with intensified statin monotherapy in patients with coronary heart disease

Contact Info

Product

Resources

About